VALIDITY OF SELF REPORTED FAMILY HISTORY OF LYMPHOMAS

何杰金氏病（HD）的风险增加，在患者的家庭成员。 如果已知先证者报告的HD家族史是准确的，则可以使用新的统计方法和储存的肿瘤组织，在不额外接触患者的情况下进行HD家族关联、遗传模式和易感基因的有效研究。 然而，没有数据存在的有效性自我报告的家族史HD或其他淋巴瘤，HD往往混淆。 在先前的一项基于人群的HD病例对照研究中，我们采访了645名女性并列举了她们的一级、二级和三级血亲，我们发现家族性HD显著过量，这是第一个基于人群的发现。 拟议的R 03研究将验证50名先证者提供的HD和其他淋巴瘤的阳性家族史，对照医疗记录和/或死亡证明报告，以探索先证者报告的家族史在未来家族性HD遗传研究中的实用性，并提供第一个基于人群的经验证家族性HD和女性相关风险的描述。 该研究将：1）通过电话采访33例HD病例和17例人群对照先证者，以获得他们报告患有HD或其他淋巴瘤的58名血亲的联系信息; 2）通过电话联系58名亲属或其近亲，以获得他们的癌症病史，并获得病理报告和出院摘要，或根据需要，死亡证明，以进行诊断审查; 4）比较报告的和记录的诊断，以计算先证者报告的HD和其他淋巴瘤家族史的有效性，对于一级、二级和选定的三级亲属; 5）描述原始人群HD病例系列中经验证的家族性HD和相关风险。 研究优势是：1）纳入基于人群的、先证者衍生的第一、第二和选定的第三亲属病史，以便结果既可推广又可延伸到第一级亲属之外; 2）验证HD和其他淋巴瘤，两者均在高风险家族中报告，但通常难以区分; 3）使用文件层级：医疗记录、死亡证明和亲属的自我报告。建立先证者报告的淋巴瘤的有效性将有助于我们确定HD先证者报告的高风险家系的有用性，这些先证者可以通过癌症登记筛查有效地识别出足够数量的高风险家系，并将扩大癌症史验证的文献，以包括HD。研究结果也对自我报告的淋巴瘤家族史的实用性有影响，用于咨询淋巴瘤家族成员有关疾病风险。

Hodgkin's disease (HD) risk is increased in family members of patients. If proband-reported family histories of HD were known to be accurate, efficient studies of HD family association, inheritance patterns and susceptibility genes could be conducted without additional patient contact, using new statistical methods and stored tumor tissues. However, no data exist on the validity of self-reported family history of HD or other lymphoma, with which HD is often confused. In a prior population-based, case- control study of HD for which we interviewed 645 women and enumerated their 1st-, 2nd-, and 3rd-degree blood relatives, we found a significant excess of familial HD, the first such population-based finding. The proposed R03 study will validate the positive family histories of HD and other lymphoma provided by 50 probands, against medical record and/or death certificate reports, to explore the utility of proband-reported family histories for future genetic studies of familial HD, and to provide the first population-based description of validated familial HD and associated risk in women. The study will: 1) interview the 33 HD case and 17 population-control probands by phone for contact information on the 58 blood relatives they had reported as having HD or other lymphoma; 2) contact the 58 relatives or their next-of-kin by phone to obtain their cancer history and access to pathology reports and discharge summaries, or, as needed, death certificates, for diagnostic review; 3) obtain the diagnostic documents, and review and classify diagnoses per cancer-registry standards; 4) compare reported and documented diagnoses to calculate validity of proband-reported family history of HD and of other lymphoma, for 1st-, 2nd-, and selected 3rd-degree relatives; 5) describe validated familial HD and associated risk in the original population-based HD case series. Study strengths are: 1) inclusion of population-based, proband-derived histories for 1st-, 2nd-, and selected 3rd- relatives, so that findings are both generalizable and extend beyond 1st-degree relatives; 2) validation of HD and of other lymphomas, both reported in high-risk families but often hard to differentiate; 3) use of a documentation hierarchy: medical record, death certificate, and relative's self-report. Establishing validity of proband-reported lymphomas will help us determine the usefulness of high-risk pedigrees reported by HD probands, who could be identified for this purpose efficiently and in adequate numbers by cancer-registry screening, and will expand the literature on cancer-history validation to include HD. Study results also have implications to the utility of self- reported family history of lymphoma for counseling lymphoma family members about disease risk.